Showing 1179 results
- https://www.novartis.com/news/media-releases/novartis-new-cosentyx-data-confirms-robust-efficacy-and-quality-life-improvements-scalp-psoriasisMajority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million…
- https://www.novartis.com/news/media-releases/novartis-forms-alliance-develop-medicines-treating-infectious-diarrheal-diseaseNovartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the…
- https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopa-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosisGlatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched…
- https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-cosentyx-label-update-include-moderate-severe-scalp-psoriasisUS label updated to include Cosentyx® (secukinumab) data in moderate-to-severe scalp psoriasis[1] - one of the difficult-to-treat types of psoriasis[2] Approximately half of all 125 million…
- https://www.novartis.com/news/media-releases/novartis-completes-subsequent-offering-period-tender-offer-advanced-accelerator-applications-saBasel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all…
- https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-kymriahtm-children-young-adults-rr-allAnalysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with…
- https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutathera-treatment-gastroenteropancreatic-neuroendocrine-tumorsLutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera…
- https://www.novartis.com/news/media-releases/novartis-exclusively-licenses-first-ophthalmology-gene-therapy-all-markets-outside-us-milestone-patients-rare-inherited-vision-lossNovartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights…
- https://www.novartis.com/news/media-releases/novartis-delivered-good-operational-performance-and-landmark-innovation-2017-entering-our-next-growth-phaseFull year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1…
- https://www.novartis.com/news/media-releases/novartis-enregistre-en-2017-une-belle-performance-operationnelle-et-des-innovations-majeures-entrant-ainsi-dans-une-nouvelle-phase-de-croissanceHausse de 2% (tcc, +1% USD) des ventes sur l'exercice complet, car l'excellente performance de nos moteurs de croissance, notamment Cosentyx et Entresto, a plus que compensé l'érosion due aux…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 118
- › Next page